$MOH (Molina Healthcare, Inc.)

$MOH {{ '2016-04-20T04:21:27+0000' | timeago}} • Announcement

$MOH said it will fund the Total Care plan purchase with available cash. Total Care is a prepaid health services plan that provides health care coverage to about 39,000 members under the Medicaid and Child Health Plus programs in 3 upstate New York counties. The deal is expected to close in 3Q16.

$UNH {{ '2018-01-17T18:35:18+0000' | timeago}} • Webcast

For 2018, health insurance provider UnitedHealth expects its profits between $16.7-17.3Bil. $UNH expects its premium revenues to reduce $400-500MM due to regulatory changes in Affordable Care Act. The company also plans to invest $200-300MM this year in artificial intelligence, data analytics etc. which would improve its engagement with customers.

$UNH {{ '2018-01-17T18:34:42+0000' | timeago}} • Webcast

UnitedHealth's 2017 medical care ratio increased 90 basis points to 82.1% vs. last year. Medical care ratio shows how much money is spent on healthcare from the premiums received by the health insurer. $UNH expects its 2018 medical care ratio to come around 81.5% plus or minus 50 basis points.

$UNH {{ '2018-01-17T18:34:08+0000' | timeago}} • Webcast

UnitedHealth's 4Q profits spiked to $3.62Bil whereas revenue was up 9% to $52.06Bil. $UNH's Health Insurance segment brings in more revenues, but Optum segment contributed more to its profits. Optum's profits were up 22% reaching $2.2Bil in 4Q. For 2017, the company reported a non-cash tax benefit of $1.22 per share due to tax reforms.

$UNH {{ '2018-01-17T13:48:18+0000' | timeago}} • Announcement

Largest US health insurer UnitedHealth's profits more than doubled in the fourth quarter to $3.61Bil due to tax benefits. $UNH also crossed $200Bil mark in revenues for FY17. The company now expects to save $1.7Bil in FY18 due to tax reforms. For 2018, the health insurer expects GAAP EPS between $11.65-11.95 and non-GAAP EPS between $12.30-12.60.

$HUM {{ '2018-01-16T20:57:20+0000' | timeago}} • Announcement

Healthcare company $HUM has appointed Luis Torres Olivera as President, Health and Well-being, for the Puerto Rico Market. Torres Olivera, who joined the company more than a decade ago, has overseen several key projects. He succeeds Earl Harper, who will be retiring at the end of February 2018.

$UNH {{ '2018-01-16T17:58:43+0000' | timeago}} • Infographic

$UNH UnitedHealth Group Incorporated Earnings AlphaGraphic: Q4 2017 Highlights

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$MOH {{ '2018-01-11T21:46:24+0000' | timeago}} • Announcement

$MOH said COO Terry Bayer will be retiring in the next several weeks. The corporate COO role will no longer be a part of $MOH's organizational structure. This is consistent with the company's shift to a flatter organizational structure that will enable the CEO to be more directly involved with business and health plan operations.

$MD {{ '2018-01-10T15:20:12+0000' | timeago}} • Announcement

$MD announced the acquisition of Tri-Valley Neonatal Medical Group, Inc., a private neonatology physician practice based in California. This was a cash transaction and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$MRK {{ '2018-01-09T20:27:32+0000' | timeago}} • Announcement

Pharma company $MRK said the FDA has granted 'Breakthrough Therapy Designation' for Lenvima, a multiple receptor tyrosine kinase inhibitor developed by Eisai in combination with Merck's anti-PD-1 therapy Keytruda for the treatment of renal cell carcinoma. The FDA action was based on the results of a multi-center study conducted in US and Europe.

$MSA {{ '2018-01-09T19:42:03+0000' | timeago}} • Announcement

$MSA BoD declared 1Q18 dividend of 35 cents per share on common stock. The dividend is payable March 10, 2018 to shareholders of record on February 14, 2018.

$MRK {{ '2018-01-09T18:45:44+0000' | timeago}} • Announcement

Merck today announced that it has received Breakthrough Therapy Designation from FDA for LENVIMA and KEYTRUDA. The combination therapy (LENVIMA & KEYTRUDA) is being jointly developed by Eisai and $MRK for treating patients with advanced and/or metastatic renal cell carcinoma. In 2017, approx. 63,990 new cases were estimated to have occurred in US.

$PRGO {{ '2018-01-08T12:05:55+0000' | timeago}} • Announcement

$PRGO named Uwe Rohrhoff as CEO, effective Jan. 15, 2018, following the retirement of John Hendrickson. Rohrhoff was the former CEO at Gerresheimer AG. Hendrickson to remain with the company until March 15, 2018 to ensure successful transition.

$OMI {{ '2018-01-05T13:04:48+0000' | timeago}} • Announcement

Healthcare solutions firm $OMI plans to organize into two units, named Global Solutions and Global Products. The move is in connection with the acquisition and integration of Halyard Health’s Surgical & Infection Prevention business. Global Solutions will contain most of Owens’ legacy business, while Global Products will contain its S&IP business.

$PFE {{ '2018-01-04T13:11:11+0000' | timeago}} • Announcement

Arvinas LLC collaborates with $PFE for the discovery and development of drug candidates using Arvinas' PROTAC Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Arvinas may receive up to $830MM in upfront and potential development and commercialization milestone payments.

$MRK {{ '2018-01-02T20:34:14+0000' | timeago}} • Announcement

Merck announced today that Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its cancer drug KEYTRUDA for treating patients with Urothelial Carcinoma, a type of bladder cancer. This approval helps $MRK to market KEYTRUDA for 4 types of cancer in Japan. The company plans to market KEYTRUDA in partnership with Taiho Pharmaceuticals.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$MRK {{ '2017-12-22T16:34:34+0000' | timeago}} • Announcement

$MRK and $PFE announced that the FDA approved STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, January 16 2018 - 1:45pm
ENZ (Enzo Biochem Inc.)
Friday, December 8 2017 - 1:30pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
RDNT (RadNet, Inc.)
Thursday, November 9 2017 - 3:30pm
GTS (Triple-S Management Corporation)
Thursday, November 9 2017 - 2:00pm
PRGO (Perrigo Company Public Limited Company)
Thursday, November 9 2017 - 1:00pm
OPK (Opko Health, Inc.)
Wednesday, November 8 2017 - 9:30pm
HUM (Humana Inc.)
Wednesday, November 8 2017 - 2:00pm
DXC (DXC Technology Company)
Tuesday, November 7 2017 - 10:00pm
ZIOP (ZIOPHARM Oncology, Inc.)
Monday, November 6 2017 - 9:30pm
VCYT (Veracyte, Inc.)
Monday, November 6 2017 - 9:30pm
MOH (Molina Healthcare, Inc.)
Thursday, November 2 2017 - 9:00pm
NVO (Novo Nordisk A/S)
Thursday, November 2 2017 - 1:16pm
CI (Cigna Corp.)
Thursday, November 2 2017 - 12:30pm
MD (MEDNAX, Inc.)
Wednesday, November 1 2017 - 2:00pm
MGLN (Magellan Health, Inc.)
Wednesday, November 1 2017 - 2:00pm
OMI (Owens & Minor Inc.)
Wednesday, November 1 2017 - 12:00pm
NVO (Novo Nordisk A/S)
Wednesday, November 1 2017 - 11:31am
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
WCG (WellCare Health Plans, Inc.)
Tuesday, October 31 2017 - 1:30pm

AlphaGraphics you may like